Ultrasonically controlled albumin-conjugated liposomes for breast cancer therapy
Source abstract
Abstract
Targeted liposomes have high potentials in the specific and effective delivery of their loaded therapeutic agents to the tumour site. Once at the tumour site, it is important that these liposomes are triggered to release their load in a controlled and effective manner. In this study, pegylated (stealth) liposomes conjugated to human serum albumin (HSA) were investigated for the delivery of a model drug (calcein) to breast cancer cells. The fluorescent results showed that calcein uptake by the two breast cancer cell lines (MDA-MB-231 and MCF-7) was significantly higher with the HSA-PEG liposomes compared to the non-targeted control liposomes. Furthermore, the exposure to low-frequency ultrasound (LFUS) resulted in a statistically significant uptake of calcein compared to the uptake without ultrasound. The described drug delivery (DD) system, which involves combining the targeted liposomal formulation with ultrasonic triggering techniques, promises a safe, effective and site-specific breast cancer therapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Ultrasound and Hyperthermia Applications · Characterization and Applications of Magnetic Nanoparticles
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemical Engineering, American University of Sharjah
Department of Biology, Chemistry and Environmental Sciences, American University of Sharjah
Biosciences and Bioengineering Research Institute, American University of Sharjah
Funding
American University of Sharjah
References (50)
Show source-provided references
1. 10.1053/svms.2003.3661710.1053/svms.2003.36617 ↗
2. 10.2217/17435889.1.3.29710.2217/17435889.1.3.297 ↗
3. 10.1016/j.cis.2017.06.01210.1016/j.cis.2017.06.012 ↗
4. 10.1016/S0168-3659(99)00248-510.1016/S0168-3659(99)00248-5 ↗
5. 10.1177/03008916030890030210.1177/030089160308900302 ↗
6. 10.1021/mp900316a10.1021/mp900316a ↗
7. 10.3389/fphys.2014.0029910.3389/fphys.2014.00299 ↗
8. 10.1016/S1040-8428(97)00015-210.1016/S1040-8428(97)00015-2 ↗
9. 10.1007/BF0183335410.1007/BF01833354 ↗
10. Satoh H, Kamma H, Ishikawa H, et al. Expression of hnRNP A2/B1 proteins in human cancer cell lines. Int J Oncol. 2000;16:763–767.
11. Sueoka E, Goto Y, Sueoka N, et al. Heterogeneous nuclear ribonucleoprotein B1 as a new marker of early detection for human lung cancers. Cancer Res. 1999;59:1404–1407.
12. 10.1097/00001813-199708000-0000610.1097/00001813-199708000-00006 ↗
13. Germain P, Metezeau P, Hellio R, et al. Internalization and biological effects of serum albumin in the breast cancer MCF-7 and MDA-MB 231 cells. Cell Mol Biol (Noisy-le-Grand). 1995;41:1119–1129.
14. 10.1016/j.ijpharm.2006.08.02610.1016/j.ijpharm.2006.08.026 ↗
15. 10.1158/0008-5472.CAN-12-168310.1158/0008-5472.CAN-12-1683 ↗
16. 10.1038/sj.neo.790009610.1038/sj.neo.7900096 ↗
17. 10.1016/S0005-2736(01)00441-210.1016/S0005-2736(01)00441-2 ↗
18. 10.1002/pol.1981.13019030210.1002/pol.1981.130190302 ↗
19. 10.1021/nn300524f10.1021/nn300524f ↗
20. Needham D, Anyarambhatla G, Kong G, et al. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. 2000;60:1197–1201.
21. 10.1021/la026604t10.1021/la026604t ↗
22. 10.2174/156802661866618060812534410.2174/1568026618666180608125344 ↗
23. 10.1016/j.ejpb.2010.04.01210.1016/j.ejpb.2010.04.012 ↗
24. 10.2174/156800961566615031110061010.2174/1568009615666150311100610 ↗
25. 10.1093/oso/9780199636556.003.000110.1093/oso/9780199636556.003.0001 ↗
26. 10.1016/S0168-3659(02)00203-110.1016/S0168-3659(02)00203-1 ↗
27. 10.1073/pnas.86.20.766310.1073/pnas.86.20.7663 ↗
28. 10.1016/j.bbrc.2005.07.10110.1016/j.bbrc.2005.07.101 ↗
29. 10.1021/la063166810.1021/la0631668 ↗
30. 10.1016/j.gene.2013.03.09510.1016/j.gene.2013.03.095 ↗
31. Levi C. Ultrasound for targeted delivery of cytotoxic drugs from liposomes [M.Sc. thesis]. Beer Sheva Israel: Ben Gurion University; 2000.
32. 10.1016/j.chemphyslip.2009.08.00310.1016/j.chemphyslip.2009.08.003 ↗
33. Maynard VM, Magin R, Strom-Jensen P R, et al. Ultrasonic absorption by liposomes. In Ultrasonic Symposium. Vol. 2; 1983. p. 806–809.
34. 10.1021/j100187a06710.1021/j100187a067 ↗
35. 10.1016/j.jpba.2013.01.04310.1016/j.jpba.2013.01.043 ↗
36. 10.1016/S0005-2736(03)00196-210.1016/S0005-2736(03)00196-2 ↗
37. 10.5012/bkcs.2011.32.4.128210.5012/bkcs.2011.32.4.1282 ↗
38. 10.1038/cr.2010.1910.1038/cr.2010.19 ↗
39. 10.1038/nrm212210.1038/nrm2122 ↗
40. 10.1186/1471-2407-9-6510.1186/1471-2407-9-65 ↗
41. 10.1158/0008-5472.CAN-17-060410.1158/0008-5472.CAN-17-0604 ↗
42. 10.1152/ajplung.00152.200210.1152/ajplung.00152.2002 ↗
43. 10.1021/acs.bioconjchem.6b0069810.1021/acs.bioconjchem.6b00698 ↗
44. 10.1073/pnas.132235611110.1073/pnas.1322356111 ↗
45. 10.1091/mbc.e04-03-018910.1091/mbc.e04-03-0189 ↗
46. 10.1016/S0140-6736(99)01244-110.1016/S0140-6736(99)01244-1 ↗
47. Jelenc J Miklavčič D Lebar AM editors. Low-frequency ultrasound in vitro: experimental system and ultrasound-induced changes of cell morphology. 2013 36th international convention on information and communication technology electronics and microelectronics (MIPRO); 2013 May 20–24; Piscataway NJ IEEE.
48. 10.1529/biophysj.108.13166410.1529/biophysj.108.131664 ↗
49. 10.17305/bjbms.2012.249710.17305/bjbms.2012.2497 ↗
50. Salkho NM, Paul V, Kawak P, et al. Ultrasonically controlled estrone-modified liposomes for estrogen-positive breast cancer therapy. Artif Cells Nanomed Biotechnol. 2018;12:1–11.